Organon & Co. (DE:7XP)
NYSE:7XP
7XP Stock Chart & Stats
€8.20
€0.22(1.45%)
At close: 4:00 PM EST
€8.20
€0.22(1.45%)
Day’s Range― - ―
52-Week Range€4.95 - €11.61
Previous CloseN/A
Volume15.00
Average Volume (3M)656.00
Market Cap
€3.04B
Enterprise Value€10.96B
Total Cash (Recent Filing)€1.12B
Total Debt (Recent Filing)€8.57B
Price to Earnings (P/E)14.1
Beta0.97
Next Earnings
Aug 11, 2026EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.95
Shares Outstanding262,609,440
10 Day Avg. Volume690
30 Day Avg. Volume656
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.47
Price to Sales (P/S)0.30
P/FCF Ratio3.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.70Price Target Upside30.52% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)2.92
Revenue Forecast (FY)€5.27B
Bulls Say, Bears Say
Bulls Say
Divestiture ProceedsDivestiture of the JADA System for roughly $440 million plus up to $25 million in milestone payments strengthens cash reserves and reduces exposure to non-core assets.
Leverage TargetCompany commitment to keep net debt to adjusted EBITDA below four times signals a focus on deleveraging that could improve credit perception and investor confidence.
Bears Say
Dividend Policy And SentimentA surprising dividend cut increased investor concern about cash allocation and may prolong negative sentiment absent a clear capital-allocation plan from management.
Governance And ComplianceInvestigation finding that U.S. wholesalers were encouraged to overpurchase Nexplanon, followed by the CEO resignation, raises governance and compliance concerns that could attract regulatory scrutiny and erode trust.
Revenue OutlookLowered revenue guidance driven by U.S. policy headwinds for Nexplanon and softness in the respiratory franchise highlights near-term revenue risk and may pressure growth expectations.
Organon News
7XP FAQ
What was Organon & Co.’s price range in the past 12 months?
Organon & Co. lowest stock price was €4.95 and its highest was €11.61 in the past 12 months.
What is Organon & Co.’s market cap?
Organon & Co.’s market cap is €3.04B.
When is Organon & Co.’s upcoming earnings report date?
Organon & Co.’s upcoming earnings report date is Aug 11, 2026 which is in 64 days.
How were Organon & Co.’s earnings last quarter?
Organon & Co. released its earnings results on Apr 30, 2026. The company reported €0.61 earnings per share for the quarter, missing the consensus estimate of €0.712 by -€0.102.
Is Organon & Co. overvalued?
According to Wall Street analysts Organon & Co.’s price is currently Undervalued.
Does Organon & Co. pay dividends?
Organon & Co. does not currently pay dividends.
What is Organon & Co.’s EPS estimate?
Organon & Co.’s EPS estimate is 0.77.
How many shares outstanding does Organon & Co. have?
Organon & Co. has 262,609,440 shares outstanding.
What happened to Organon & Co.’s price movement after its last earnings report?
Organon & Co. reported an EPS of €0.61 in its last earnings report, missing expectations of €0.712. Following the earnings report the stock price went down -0.958%.
Which hedge fund is a major shareholder of Organon & Co.?
Currently, no hedge funds are holding shares in DE:7XP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€10.70 (30.52% Upside)
€10.70 (30.52% Upside)
Blogger Sentiment
Bullish
DE:7XP Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €306.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.66%
12-Months-Change
Fundamentals
Return on Equity
29.87%
Trailing 12-Months
Asset Growth
-1.22%
Trailing 12-Months
Company Description
Organon & Co.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
7XP Company Deck
7XP Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: several strong, tangible positives (stable full-year guidance, robust biosimilars growth—Hadlima +61% ex-FX—Vtama/Emgality momentum, >$200M cost savings, $960M free cash flow, $390M Jada divestiture and active deleveraging). Offsetting these are meaningful near-term commercial and margin headwinds (revenue down ~3% FY, Q4 -8% CC; Nexplanon channel and policy impacts with Q4 Nexplanon -20% ex-FX; respiratory pricing pressure; gross margin deterioration and a Q4 goodwill impairment), plus some governance/uncertainty from unresolved audit matters. Management expects flat 2026 results and continued focus on cost discipline and balance sheet repair, but several execution and market risks remain.View all DE:7XP earnings summaries7XP Stock 12 Month Forecast
Average Price Target
€10.70
▲(30.52% Upside)
Technical Analysis
Options Prices
Currently, No data available
---